GNOMX Corp. Awarded Phase 1 BARDA DRIVe Contract to Develop Immune Dysregulation Host-based Assay for Predicting Sepsis Patient Readmission Risk
GNOMX Corp. has been awarded a $749,700 contract by the Division of Research, Innovation, and Ventures (DRIVe) within the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and...
20-Nov-2024 9:50 AM EST
Add to Favorites